These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32034790)

  • 21. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New drugs in oncology--features of clinical trials for market authorisation and arguments for the rapid implementation of independent clinical trials following approval].
    Ludwig WD; Schott G
    Onkologie; 2013; 36 Suppl 2():17-22. PubMed ID: 23549032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.
    Imaoka H; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Watanabe K; Umemoto K; Kimura G; Suzuki Y; Ikeda M
    Endocr Relat Cancer; 2017 Sep; 24(9):475-483. PubMed ID: 28684542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II design: history and evolution.
    Rubinstein L
    Chin Clin Oncol; 2014 Dec; 3(4):48. PubMed ID: 25841529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
    Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
    J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
    Tate Thigpen J
    Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.
    Teng Z; Gupta N; Hua Z; Liu G; Samnotra V; Venkatakrishnan K; Labotka R
    Clin Transl Sci; 2018 Mar; 11(2):218-225. PubMed ID: 29168990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
    Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
    Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.
    Tan A; Porcher R; Crequit P; Ravaud P; Dechartres A
    J Clin Oncol; 2017 May; 35(15):1686-1694. PubMed ID: 28375786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
    Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
    Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma.
    Nakashima K; Horita N; Nagai K; Manabe S; Murakami S; Ota E; Kaneko T
    J Thorac Oncol; 2016 Sep; 11(9):1574-85. PubMed ID: 27178983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
    Rogers L; Zhang P; Vogelbaum MA; Perry A; Ashby LS; Modi JM; Alleman AM; Galvin J; Brachman D; Jenrette JM; De Groot J; Bovi JA; Werner-Wasik M; Knisely JPS; Mehta MP
    J Neurosurg; 2018 Jul; 129(1):35-47. PubMed ID: 28984517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of tumor burden versus progression-free survival for Phase II decision making.
    Fridlyand J; Kaiser LD; Fyfe G
    Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial.
    Kurokawa Y; Boku N; Yamaguchi T; Ohtsu A; Mizusawa J; Nakamura K; Fukuda H
    ESMO Open; 2016; 1(1):e000031. PubMed ID: 27843586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
    Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
    BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.